Search
Resomelagon
go.drugbank.com/drugs/DB21579InvestigationalThe usage of the INN stem '-melagon' in the name indicates that Resomelagon is a non-peptidic melanocortin receptor agonist. … Resomelagon is under investigation in clinical trial NCT06917001 (Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)).
Gridegalutamide
go.drugbank.com/drugs/DB21593InvestigationalThe usage of the INN stem '-lutamide' in the name indicates that Gridegalutamide is a non-steroid antiandrogen. … Gridegalutamide is under investigation in clinical trial NCT04428788 (Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer).
Lucanthone
go.drugbank.com/drugs/DB04967InvestigationalOne of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).
DT-DEC01
go.drugbank.com/drugs/DB19433ExperimentalDT-DEC01 is a novel Dystrophin Expressing Chimeric (DEC) cell therapy being investigated by Dystrogen Therapeutics Corporation.
HSV-2 theracine
go.drugbank.com/drugs/DB05811ExperimentalHSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Silver nitrate
go.drugbank.com/drugs/DB11080ApprovedIt is often used as a precursor to other silver-containing compounds.
Imipramine oxide
go.drugbank.com/drugs/DB13782ExperimentalSynonyms: Imipramine N-oxideCategories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeLofepramine
go.drugbank.com/drugs/DB13411ExperimentalCategories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDesirudin
go.drugbank.com/drugs/DB11095ApprovedWithdrawnIt has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis.
CYC116
go.drugbank.com/drugs/DB05198InvestigationalCyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition